News and updates

Agendia Announces Level 1 Inclusion of MammaPrint® Breast Cancer Test in Updated National Comprehensive Cancer Network® (NCCN) Guidelines

October 9, 2018

PRESS RELEASE Agendia Announces Level 1 Inclusion of MammaPrint® Breast Cancer Test in Updated National Comprehensive Cancer Network® (NCCN) Guidelines The NCCN recommends Agendia’s MammaPrint® breast cancer test with the highest level of evidence for early-stage breast cancer patients with estrogen receptor-positive, lymph-node negative and lymph-node positive (LN+ 1-3)  MammaPrint is now the only genomic…

Read more

Agendia and Genecast Biotechnology Partner to Launch MammaPrint and BluePrint in China

September 18, 2018

For the first time, early-stage breast cancer patients and their physicians in China can access clinically validated and prospectively proven tests for breast cancer risk of recurrence and molecular subtyping IRVINE, CALIF., U.S., AMSTERDAM, NETHERLANDS and BEIJING, CHINA – 18 September 2018 – Agendia, Inc., a world leader in precision oncology, announced that it has…

Read more

US Oncology Research Joins Agendia’s FLEX Big Data Initiative, Accelerating Diagnostic Discoveries in Breast Cancer and Enabling Precision Oncology

August 23, 2018

Dataset of up to 10,000 full genome profiles matched with complete clinical data will provide representative resource for breast cancer research IRVINE, CALIF., U.S., THE WOODLANDS, TEXAS, U.S., and AMSTERDAM, NETHERLANDS (23 August 2018) – Agendia, Inc., a world leader in precision oncology, announced today that US Oncology Research, one of the nation’s largest research…

Read more

An Update on Agendia’s Precision Oncology Achievements in Breast Cancer

August 7, 2018

  As we close out the first half of 2018, I’d like to take a moment to reflect on Agendia’s recent achievements as a global leader in precision oncology and provide an update on forward-looking expansions that will have a positive impact on patients and their doctors. Our mission is to provide best in class…

Read more